Bayforest Capital LTD Apellis Pharmaceuticals, Inc. Transaction History
Bayforest Capital LTD
- $121 Billion
- Q1 2025
A detailed history of Bayforest Capital LTD transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Bayforest Capital LTD holds 52,338 shares of APLS stock, worth $886,082. This represents 0.5% of its overall portfolio holdings.
Number of Shares
52,338
Previous 9,839
431.94%
Holding current value
$886,082
Previous $314 Million
93.98%
% of portfolio
0.5%
Previous 0.39%
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$208 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$207 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$201 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$172 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$163 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $1.86B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...